Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Urinary Assay for Alzheimer's Disease Verified by Clinical Studies

By Labmedica staff writers
Posted on 14 Jan 2008
A urinary assay adds significant useful information in the diagnosis of Alzheimer's disease (AD), particularly for the family physician.

AlzheimAlert is a non-invasive accurate urine test that can help in the diagnosis of AD. More...
The AlzheimAlert test detects the presence of a brain protein--neural thread protein (NTP)--which is elevated in the urine of patients with Alzheimer's disease.

The test AlzheimAlert was developed and produced by Nymox Pharmaceutical Corp. (Hasbrouck Heights, NJ, USA). A positive report on AlzheimAlert was published in the January 2008 issue of the journal Expert Review of Molecular Diagnostics. The article was written by Ira Goodman, M.D., director of neurology, Orlando Regional HealthCare, Florida (Orlando, FL, USA) and associate clinical professor, departments of neurology and medicine, University of Florida School of Medicine (Gainesville, FL, USA). The article reviews the large number of basic research and clinical studies to date concerning the accuracy and specificity of the Nemox's urinary assay and documents several of Dr. Goodman's own clinical cases where the assay results proved useful in either arriving at a diagnosis of AD or in helping to rule it out.

One report involved a 39-year-old year male with an elevated AlzheimAlert result supportive of an AD diagnosis. Extensive testing confirmed a rare form of familial AD. A second of the researcher's cases involved a 54-year-old male with a history of cognitive decline and an elevated AlzheimAlert result. Eventually, a brain biopsy confirmed the diagnosis. In other cases described in the article, negative AlzheimAlert results helped to lead to other diagnoses, which were not AD.

The test has the CE Mark, allowing it to be marketed in Europe, and is also available to physicians in the United States through the company's Clinical Laboratory Improvement Amendments- (CLIA)-approved clinical reference laboratory. Data showing the high clinical accuracy and utility of the test have been frequently reported in the peer-reviewed literature, including the Journal of Clinical Laboratory Analysis (Volume 8, 2007) and the Journal of the American Medical Directors Association (Volume 21, 2007).


Related Links:
Orlando Regional HealthCare
University of Florida School of Medicine
Nymox Pharmaceutical Corp

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.